Page 3


  • Two test tubes pour different-colored liquids into a beaker in an illustration representative of biopharma mergers.
    Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip

    Homology enters reverse merger with Q32 Bio

    The deal, which will result in a combined company operating under Q32's name, comes months after Homology laid off much of its staff.

  • Illustration of lung cancer
    Image attribution tooltip
    SciePro via Getty Images
    Image attribution tooltip

    FDA approves new Bristol Myers drug for lung cancer

    Acquired via a $4 billion biotech buyout, Augtyro is one of an array of new products the pharma hopes will offset patent expirations for current top sellers.

  • A sign showing Gilead's logo
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Gilead expands Arcellx cancer cell therapy deal

    The deal gives Gilead an estimated 13% ownership in Arcellx and extends the company’s cash runway into 2027.

  • A grey exterior sign with Alkermes' written on it sits in a bed of flowers outside a glass office building.
    Image attribution tooltip
    Permission granted by Karissa Waddick
    Image attribution tooltip

    Alkermes separates cancer drug business as new company Mural

    Now independent Mural Oncology will focus on advancing a pipeline of engineered cytokines for cancer, while Alkermes has recast itself as a “pure-play” neuroscience company.

  • People walk past the Nasdaq MarketSite on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    A gene editing biotech’s struggles end with reverse merger

    Since halting work on a sickle cell treatment early this year, Graphite Bio has laid off staff, shed assets and, now, agreed to be subsumed via a merger with Lenz Therapeutics.

  • Boxes of the diabetes drug Ozempic are seen on a pharmacy counter.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    New AMA policies target GLP-1 coverage, corporate medicine

    The lobbying group urged broader health insurance coverage for treating obesity, including with GLP-1 agonists like Wegovy.

  • A 3D rendered image of a neuron cell network on black background.
    Image attribution tooltip
    koto_feja via Getty Images
    Image attribution tooltip
    ALS drug development

    Forbion-backed biotech raises $138M to develop ALS drug

    The Series A round for three-year-old startup VectorY is one of the largest private financings in Europe this year, Forbion said.

  • An illustration of T cells attacking a cancer cell
    Image attribution tooltip
    Peddalanka Ramesh Babu via Getty Images
    Image attribution tooltip

    Novartis licenses Legend cell therapy for lung cancer

    With the deal, the Swiss pharma is exploring a tumor target, DLL3, that’s thwarted past drugmaker efforts to attack it.

  • Forge Biologics' headquarters in Columbus, Ohio, covered in snow.
    Image attribution tooltip
    Courtesy of Forge Biologics
    Image attribution tooltip

    Ajinomoto spices up its biopharma business with gene therapy deal

    Forge Biologics operates a contract manufacturing business and develops its own gene therapies, which appears to have attracted the Japan-based food and biotechnology company.

  • An illustration of red blood cells.
    Image attribution tooltip
    Pixelimage via Getty Images
    Image attribution tooltip

    Anthos blood thinner bests Xarelto on safety in mid-stage study

    Trial results add to evidence that so-called Factor XIa inhibitors could have less bleeding risk than currently available oral anticoagulants like Xarelto.

    Updated Nov. 14, 2023
  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Douglas Cliff via Getty Images
    Image attribution tooltip
    Obesity drugs

    Wegovy study details revive debate over GLP-1 impact on devices

    Shares in several heart device makers, which have been battered over the perceived impact of obesity medicines, rose this week following AHA data on Novo’s therapy.

  • A photo of Sekar Kathiresan, CEO of Verve Therapeutics
    Image attribution tooltip
    Seth Babin/BioPharma Dive
    Image attribution tooltip
    Gene editing

    First look at Verve study data offers base editing ‘proof of principle’

    Early clinical trial results showed Verve’s therapy can substantially lower bad cholesterol. Still, investors sent the biotech’s shares down by 40% Monday.

  • A Novo Nordisk sign is seen on the side of a building.
    Image attribution tooltip
    hapabapa via Getty Images
    Image attribution tooltip
    Obesity drugs

    Detailed trial data confirm Wegovy heart benefit

    As GLP-1 drugs for weight loss take off, the results for Novo Nordisk’s treatment could help convince insurers to expand coverage.

  • Valneva’s chikungunya vaccine approved by FDA

    The preventive shot is the first to receive regulatory approval for the mosquito-borne illness, which is growing in prevalence worldwide.

    FDA
  • White flags bearing Novo Nordisk's logo are seen against a blue sky.
    Image attribution tooltip
    Courtesy of Novo Nordisk
    Image attribution tooltip
    Obesity drugs

    Novo takes aim at obesity drug shortages with $6B manufacturing plan

    The maker of Wegovy and Ozempic plans to expand production in its home country of Denmark to help meet surging demand for the GLP-1 drugs.

  • A photo of the street sign for Wall Street, in front of a row of American flags.
    Image attribution tooltip
    hapabapa via Getty Images
    Image attribution tooltip

    CAR-T biotech Cargo Therapeutics prices $281M IPO

    While the proceeds came in at the low end of Cargo’s expected range, the IPO is the fourth largest this year for a biotech company.

  • A photo of a nerve cell attacked by antibodies
    Image attribution tooltip
    peterschreiber.media via Getty Images
    Image attribution tooltip

    Atara’s cell therapy approach to MS falls short in study

    Shares in the biotech tumbled by 75% as results from a Phase 2 trial showed more improvement in participants given a placebo.

  • Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip
    Obesity drugs

    AstraZeneca stays in GLP-1 drug race with new deal

    AstraZeneca is paying $185 million upfront to gain access to an experimental GLP-1 drug from China-based biotech Eccogene.

  • A sign showing the Takeda Oncology logo.
    Image attribution tooltip
    Jacob Bell
    Image attribution tooltip

    Takeda secures FDA approval for colon cancer drug

    The pharma paid $400 million to license the drug from Hutchmed earlier this year in an effort to bolster its oncology business.

    FDA
  • The sign identifying the FDA headquarters in front of its building in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly rival to weight loss drug Wegovy approved by FDA

    The pharmaceutical company will sell the GLP-1 drug, branded as Zepbound, at a list price about 20% lower than Novo Nordisk's competing therapy.

    Updated Nov. 8, 2023
    FDA
  • The logo of German pharmaceuticals and chemicals giant Bayer stands over Bayer corporate offices on September 14, 2016 in Berlin, Germany.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    Bayer’s new CEO signals business shake-up, plans to slash management

    Company head Bill Anderson said Bayer may separate its consumer health or crop science business, and signaled “significant” layoffs are in the future.

  • A photo of a Biogen sign
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Biogen says growth is coming, but won’t specify when

    CEO Chris Viehbacher said the company has “the elements to think about a return to topline growth.” Yet, that goal hinges on the successful commercialization of multiple new products.

    Updated Nov. 8, 2023
  • The Federal Trade Commission headquarters is pictured in Washington, D.C. The agency's proposed noncompete ban may face legal challenges on several grounds.
    Image attribution tooltip
    RiverNorthPhotography via Getty Images
    Image attribution tooltip

    FTC challenges patents held by nine big drugmakers, citing unfair competition

    The agency claims intellectual property for emergency allergy shot EpiPen and asthma medication Advair was “improperly listed” in an FDA database.

  • A conceptual illustration of neural activity in a brain.
    Image attribution tooltip
    nopparit via Getty Images
    Image attribution tooltip

    Biogen, Sage set price of postpartum depression pill at $15,900

    The price is below what some analysts had predicted and significantly less than $34,000 Sage initially set for its earlier postpartum infusion, Zulresso.

  • A skyline of tall buildings is seen at sunset.
    Image attribution tooltip
    Chris McGrath via Getty Images
    Image attribution tooltip

    Flagship expands into Asia-Pacific with new Singapore hub

    The biotech company creator hopes its new office will help its portfolio companies grow and strike partnerships in the region.